Abstract
BioDrugs Company Profiles provide brief overviews of emerging and established companies in the biotechnology industry, featuring information on strategies, product development and R&D partnering. CellControl is a biotech company specialising in the fusion of tumour diagnostics and therapeutics, with the goal of achieving breakthroughs for cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001 May; 7(5): 1154–62
Grant SC, Kirs MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999 Jun; 5: 1319–23
Foon KA, Bhattacharya-Chatterjee M. Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 2001 May; 7(5): 1112–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Behnke, N. CellControl AG. BioDrugs 16, 209–211 (2002). https://doi.org/10.2165/00063030-200216030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-200216030-00005